StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Wednesday. The company has a market cap of $428,155.00, a PE ratio of -0.04 and a beta of 0.73. The firm has a fifty day moving average price of $0.05 and a two-hundred day moving average price of $0.05. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.52.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.